The medical center at the University of Toronto says it will stop using an experimental new injection of chemotherapy called MEXT, which was developed by a team led by a U.S. doctor.
The drug, which has never been approved for the treatment of advanced cancer, has become a rallying cry for cancer patients who are frustrated that they can’t get the drug at the local pharmacies.
The move follows months of public outcry about MEXT and other treatments that were not FDA-approved.
“It’s the first time in a long time we’ve had a decision that this is the right thing to do,” said Dr. Richard Molloy, chief medical officer of the Toronto-based Cancer Care Research Institute.
“We’ve had other companies say they’re not going to use it.
It’s the wrong thing to say.”
MEXT is made by GlaxoSmithKline and uses a special form of the anti-cancer drug, known as a PEG, which is extracted from a plant.
A handful of people have received MEXT in recent months, and Molloys said there are a handful more who are still receiving treatment from the treatment.
He declined to name them.
MollOY said the drug is not safe, but that it’s better than other alternatives.
MEXT was approved in 2013 and it’s only now getting a foothold in the U.K. because the government is considering lifting restrictions on its use.
The U.N. Food and Agriculture Organization said in November that a number of new drugs made by companies with connections to the pharmaceutical industry have shown promise in treating advanced cancer patients.
Some of the newer treatments have gained traction, such as PEG-7606, a treatment that’s been approved by the U